Cardiovascular Performance Improvements including Lower Blood Pressure Discovered from Human Clinical Trial using Lexaria's DehydraTECH(TM) Powered TurboCBD(TM) Capsules

Author's Avatar
Apr 12, 2019
Article's Main Image

KELOWNA, BC / ACCESSWIRE / February 21, 2019 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, is pleased to announce additional significant findings upon completion of further data analyses from its 2018 randomized, placebo-controlled, double-blinded European human clinical study that evaluated TurboCBDâ„¢, the Company's proprietary, DehydraTECHâ„¢ powered, cannabidiol (''CBD'') fortified hemp-oil capsule.